国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Americas

US FDA issues emergency use authorization for first COVID-19 vaccine

Xinhua | Updated: 2020-12-12 14:08
Share
Share - WeChat
In this file photo illustration taken on Nov 23, 2020, shows a syringe and a bottle reading "COVID-19 Vaccine" next to the Pfizer company logo. [Photo/Agencies]

WASHINGTON -- The US Food and Drug Administration (FDA) Friday issued authorization for emergency use of the first COVID-19 vaccine in the United States.

The first Emergency Use Authorization (EUA) was issued to the COVID-19 vaccine of American drugmaker Pfizer in partnership with German company BioNTech, allowing the vaccine to be distributed in the United States.

The FDA has determined that Pfizer-BioNTech COVID-19 vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech COVID-19 vaccine may be effective in preventing COVID-19, said the FDA in a statement.

The data also show that the known and potential benefits outweigh the known and potential risks, supporting the vaccine's use in millions of people 16 years of age and older, said the FDA.

"The FDA's authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world," said FDA Commissioner Stephen Hahn.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," he said in a statement.

The Pfizer-BioNTech vaccine contains a small piece of the SARS-CoV-2 virus's mRNA that instructs cells in the body to make the virus's distinctive "spike" protein.

When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

The vaccine is administered as a series of two doses, three weeks apart.

Global COVID-19 cases surpassed 70 million on Friday, according to the Center for Systems Science and Engineering at Johns Hopkins University. The United States reported the most cases and deaths around the world as of 4:28 pm local time (2128 GMT), numbering 15,758,661 and 293,785, respectively.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
安福县| 石阡县| 若尔盖县| 新乐市| 廊坊市| 甘德县| 遵义市| 醴陵市| 静安区| 石河子市| 武隆县| 永康市| 绥德县| 竹溪县| 门源| 黔江区| 南通市| 卓尼县| 寿光市| 阿克陶县| 宜丰县| 永靖县| 闸北区| 丘北县| 扎赉特旗| 青川县| 东乌| 寿光市| 陕西省| 化德县| 苍山县| 沐川县| 合作市| 林西县| 永春县| 揭阳市| 潞西市| 迁西县| 兴城市| 连城县| 邹平县|